Skip to main content
TipRanks
Go Ultimate75% OFF

Compare Gyre Therapeutics (L9S) vs. Competitors

1 Followers

Comparison Results

Comparison results
NamePriceMarket CapP/E RatioYearly GainAnalyst ConsensusAnalyst Price TargetCompareTop Analysts' Price TargetSmart ScoreFollow
DE:L9SGyre TherapeuticsEUR 3.94EUR 478.30M-16.27-42.48%Moderate BuyUnlock the DE:L9S analyst price target with TipRanks PremiumDE:L9SUnlock the DE:L9S top-analyst price target with TipRanks Premium
GALTGalectin Therapeutics$2.91$293.55M-8.48-51.50%Moderate BuyUnlock the GALT analyst price target with TipRanks PremiumDE:L9S vs GALTUnlock the GALT top-analyst price target with TipRanks Premium
IVAInventiva$3.22$759.72M-5.45-20.69%Strong BuyUnlock the IVA analyst price target with TipRanks PremiumDE:L9S vs IVAUnlock the IVA top-analyst price target with TipRanks Premium
SGMTSagimet Biosciences, Inc. Class A$9.85$702.97M-8.2326.12%Strong BuyUnlock the SGMT analyst price target with TipRanks PremiumDE:L9S vs SGMTUnlock the SGMT top-analyst price target with TipRanks Premium
AVLNAvalyn Pharma Inc$27.92$1.24B-11.43-5.32%Moderate BuyUnlock the AVLN analyst price target with TipRanks PremiumDE:L9S vs AVLNUnlock the AVLN top-analyst price target with TipRanks Premium
VCREVicore Pharma Holding AB Sponsored ADR$10.12$286.88M-5.49-24.83%Strong BuyUnlock the VCRE analyst price target with TipRanks PremiumDE:L9S vs VCREUnlock the VCRE top-analyst price target with TipRanks Premium

Performance Comparison

-75%-50%-25%0%25%50%75%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Performance comparison by fund
TickerCompany NamePriceChange% Change
DE:L9SGyre Therapeutics3.94-2.91-42.48%
GALTGalectin Therapeutics2.91-3.28-52.99%
IVAInventiva3.22-0.96-22.97%
SGMTSagimet Biosciences, Inc. Class A9.852.0325.96%
AVLNAvalyn Pharma Inc27.92-1.57-5.32%
VCREVicore Pharma Holding AB Sponsored ADR10.12-3.34-24.83%
Compare key indicators and discover each stock’s average analyst price target, as well as the latest recommendations by top Wall Street experts